Skip to content

Study · Non-randomized trial · n = 36 · 2001

8 results

Improvement of IVF outcome in poor responders by discontinuation of GnRH analogue during the gonadotropin stimulation phase--a function of improved embryo quality.

Schachter M, Friedler S, Raziel A, Strassburger D, Bern O, Ron-el R

Journal of assisted reproduction and genetics1 Apr 2001Cited by 23 (Europe PMC)

PMID11432110 (opens in a new tab)PMCIDPMC3455367 (opens in a new tab)DOI10.1023/a:1009476411762 (opens in a new tab)PepBankPUB-11432110
Source linkPubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In IVF poor responders, stopping nafarelin increased peak estradiol by 16.9% versus continued nafarelin, without statistical significance.

    In plain wordsStopping nafarelin increased peak estradiol compared with continuing it, but the difference was not significant.

    Peptide
    Nafarelin
    Outcome
    IncreasePeak estradiol
    Study

    n = 36

    Comparator
    Continued nafarelin standard cycle
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    600 mcg/d initially, stopped after 5 days of hMG stimulationAs given in this study (human).

    Measurements

    Peak estradiol, percent change in N-stop cycle vs standard cycle
    16.9%
    per-patient change, N-stop vs standard cycle

    Source sentences

    Summary
    Peak estradiol (E2) and number of aspirated oocytes were increased in the N-stop cycle (+16.9% and +28%, respectively), but insignificantly so.
    4 context sentences
    Summary · context
    Prospective case-control evaluation compared with same patient's previous performance.
    Summary · context
    Thirty-six patients enrolled in an IVF program were treated in two consecutive cycles.
    Summary · context
    The first with a standardized protocol utilizing midluteal administration of Nafarelin (N) 600 mcg/d continued throughout the stimulation phase with human menopausal gonadotropin (hMG) until follicles of 20 mm were identified by transvaginal ultrasound (Standard group).
    Summary · context
    Patients with a poor response in the Standard cycle were treated in the subsequent cycle with N and hMG initially in a similar manner, then N was stopped after 5 days of hMG stimulation (N-stop group).
  2. 02HumanNon-randomized trialEfficacy outcome

    In IVF poor responders, stopping nafarelin increased aspirated oocytes by 28% versus continued nafarelin, without statistical significance.

    In plain wordsStopping nafarelin increased collected eggs compared with continuing it, but the difference was not significant.

    Peptide
    Nafarelin
    Outcome
    IncreaseAspirated oocytes
    Study

    n = 36

    Comparator
    Continued nafarelin standard cycle
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    600 mcg/d initially, stopped after 5 days of hMG stimulationAs given in this study (human).

    Measurements

    Aspirated oocytes, percent change in N-stop cycle vs standard cycle
    28%
    per-patient change, N-stop vs standard cycle

    Source sentences

    Summary
    Peak estradiol (E2) and number of aspirated oocytes were increased in the N-stop cycle (+16.9% and +28%, respectively), but insignificantly so.
    4 context sentences
    Summary · context
    Prospective case-control evaluation compared with same patient's previous performance.
    Summary · context
    Thirty-six patients enrolled in an IVF program were treated in two consecutive cycles.
    Summary · context
    The first with a standardized protocol utilizing midluteal administration of Nafarelin (N) 600 mcg/d continued throughout the stimulation phase with human menopausal gonadotropin (hMG) until follicles of 20 mm were identified by transvaginal ultrasound (Standard group).
    Summary · context
    Patients with a poor response in the Standard cycle were treated in the subsequent cycle with N and hMG initially in a similar manner, then N was stopped after 5 days of hMG stimulation (N-stop group).
  3. 03HumanNon-randomized trialEfficacy outcome

    In IVF poor responders, stopping nafarelin increased the percentage of cleaving embryos by 27.9% versus continued nafarelin (p = 0.03).

    In plain wordsStopping nafarelin increased embryo cleavage compared with continuing it in IVF poor responders.

    Peptide
    Nafarelin
    Outcome
    IncreaseEmbryo cleavage
    Study

    n = 36

    Comparator
    Continued nafarelin standard cycle
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    600 mcg/d initially, stopped after 5 days of hMG stimulationAs given in this study (human).

    Measurements

    Cleaving embryos, percent change in N-stop cycle vs standard cycle
    27.9%
    per-patient change, N-stop vs standard cycle

    Source sentences

    Summary
    The percent of cleaving embryos was significantly increased by 27.9% (p = 0.03) in the N-stop cycle, as embryo morphology was improved by 22% (p = 0.02).
    4 context sentences
    Summary · context
    Prospective case-control evaluation compared with same patient's previous performance.
    Summary · context
    Thirty-six patients enrolled in an IVF program were treated in two consecutive cycles.
    Summary · context
    The first with a standardized protocol utilizing midluteal administration of Nafarelin (N) 600 mcg/d continued throughout the stimulation phase with human menopausal gonadotropin (hMG) until follicles of 20 mm were identified by transvaginal ultrasound (Standard group).
    Summary · context
    Patients with a poor response in the Standard cycle were treated in the subsequent cycle with N and hMG initially in a similar manner, then N was stopped after 5 days of hMG stimulation (N-stop group).
  4. 04HumanNon-randomized trialEfficacy outcome

    In IVF poor responders, stopping nafarelin improved embryo morphology by 22% versus continued nafarelin (p = 0.02).

    In plain wordsStopping nafarelin improved embryo appearance compared with continuing it in IVF poor responders.

    Peptide
    Nafarelin
    Outcome
    Direction not reportedEmbryo morphology
    Study

    n = 36

    Comparator
    Continued nafarelin standard cycle
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    600 mcg/d initially, stopped after 5 days of hMG stimulationAs given in this study (human).

    Measurements

    Embryo morphology, percent improvement in N-stop cycle vs standard cycle
    22%
    per-patient change, N-stop vs standard cycle

    Source sentences

    Summary
    The percent of cleaving embryos was significantly increased by 27.9% (p = 0.03) in the N-stop cycle, as embryo morphology was improved by 22% (p = 0.02).
    4 context sentences
    Summary · context
    Prospective case-control evaluation compared with same patient's previous performance.
    Summary · context
    Thirty-six patients enrolled in an IVF program were treated in two consecutive cycles.
    Summary · context
    The first with a standardized protocol utilizing midluteal administration of Nafarelin (N) 600 mcg/d continued throughout the stimulation phase with human menopausal gonadotropin (hMG) until follicles of 20 mm were identified by transvaginal ultrasound (Standard group).
    Summary · context
    Patients with a poor response in the Standard cycle were treated in the subsequent cycle with N and hMG initially in a similar manner, then N was stopped after 5 days of hMG stimulation (N-stop group).
  5. 05HumanNon-randomized trialEfficacy outcome

    In IVF poor responders, stopping nafarelin increased oocytes per hMG ampoule by 32.5% versus continued nafarelin (p = 0.04).

    In plain wordsStopping nafarelin increased eggs collected per medication ampoule compared with continuing it.

    Peptide
    Nafarelin
    Outcome
    IncreaseOocytes per hMG ampoule
    Study

    n = 36

    Comparator
    Continued nafarelin standard cycle
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    600 mcg/d initially, stopped after 5 days of hMG stimulationAs given in this study (human).

    Measurements

    Oocytes retrieved per hMG ampoule, percent change in N-stop cycle vs standard cycle
    32.5%
    per-patient change, N-stop vs standard cycle

    Source sentences

    Summary
    The efficacy of gonadotropin treatment was enhanced in the N-stop cycle, as expressed by a 32.5% increase in oocytes retrieved per hMG ampoule administered (p = 0.04).
    4 context sentences
    Summary · context
    Prospective case-control evaluation compared with same patient's previous performance.
    Summary · context
    Thirty-six patients enrolled in an IVF program were treated in two consecutive cycles.
    Summary · context
    The first with a standardized protocol utilizing midluteal administration of Nafarelin (N) 600 mcg/d continued throughout the stimulation phase with human menopausal gonadotropin (hMG) until follicles of 20 mm were identified by transvaginal ultrasound (Standard group).
    Summary · context
    Patients with a poor response in the Standard cycle were treated in the subsequent cycle with N and hMG initially in a similar manner, then N was stopped after 5 days of hMG stimulation (N-stop group).
  6. 06HumanNon-randomized trialEfficacy outcome

    In IVF poor responders, 3 of 36 cycles were cancelled after stopping nafarelin versus one in the standard cycle.

    In plain wordsMore cycles were cancelled after stopping nafarelin than during continued treatment.

    Peptide
    Nafarelin
    Outcome
    IncreaseCancelled cycles
    Study

    n = 36

    Comparator
    Continued nafarelin standard cycle
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    600 mcg/d initially, stopped after 5 days of hMG stimulationAs given in this study (human).

    Measurements

    Cancelled cycles
    3 cycles
    N-stop cycle, of 36
    Cancelled cycles
    1 cycles
    standard protocol cycle

    Source sentences

    Summary
    Three cycles of 36 were cancelled during the N-stop cycle, whereas only one was cancelled in the standard protocol cycle.
    4 context sentences
    Summary · context
    Prospective case-control evaluation compared with same patient's previous performance.
    Summary · context
    Thirty-six patients enrolled in an IVF program were treated in two consecutive cycles.
    Summary · context
    The first with a standardized protocol utilizing midluteal administration of Nafarelin (N) 600 mcg/d continued throughout the stimulation phase with human menopausal gonadotropin (hMG) until follicles of 20 mm were identified by transvaginal ultrasound (Standard group).
    Summary · context
    Patients with a poor response in the Standard cycle were treated in the subsequent cycle with N and hMG initially in a similar manner, then N was stopped after 5 days of hMG stimulation (N-stop group).
  7. 07HumanNon-randomized trialEfficacy outcome

    In IVF poor responders, 7 of 36 patients conceived during the nafarelin-stop protocol.

    In plain wordsSeven patients conceived during the nafarelin-stop protocol for IVF poor responders.

    Peptide
    Nafarelin
    Outcome
    Not applicableConception
    Study

    n = 36

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    600 mcg/d initially, stopped after 5 days of hMG stimulationAs given in this study (human).

    Measurements

    Patients who conceived
    7 patients
    N-stop protocol, of 36 patients

    Source sentences

    Summary
    Of the 36 patients, 7 conceived in the N-stop protocol and 5 are ongoing pregnancies.
    4 context sentences
    Summary · context
    Prospective case-control evaluation compared with same patient's previous performance.
    Summary · context
    Thirty-six patients enrolled in an IVF program were treated in two consecutive cycles.
    Summary · context
    The first with a standardized protocol utilizing midluteal administration of Nafarelin (N) 600 mcg/d continued throughout the stimulation phase with human menopausal gonadotropin (hMG) until follicles of 20 mm were identified by transvaginal ultrasound (Standard group).
    Summary · context
    Patients with a poor response in the Standard cycle were treated in the subsequent cycle with N and hMG initially in a similar manner, then N was stopped after 5 days of hMG stimulation (N-stop group).
  8. 08HumanNon-randomized trialEfficacy outcome

    In IVF poor responders, 5 of 36 patients had ongoing pregnancies during the nafarelin-stop protocol.

    In plain wordsFive patients had ongoing pregnancies during the nafarelin-stop protocol for IVF poor responders.

    Peptide
    Nafarelin
    Outcome
    Not applicableOngoing pregnancies
    Study

    n = 36

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    600 mcg/d initially, stopped after 5 days of hMG stimulationAs given in this study (human).

    Measurements

    Ongoing pregnancies
    5 patients
    N-stop protocol, of 36 patients

    Source sentences

    Summary
    Of the 36 patients, 7 conceived in the N-stop protocol and 5 are ongoing pregnancies.
    4 context sentences
    Summary · context
    Prospective case-control evaluation compared with same patient's previous performance.
    Summary · context
    Thirty-six patients enrolled in an IVF program were treated in two consecutive cycles.
    Summary · context
    The first with a standardized protocol utilizing midluteal administration of Nafarelin (N) 600 mcg/d continued throughout the stimulation phase with human menopausal gonadotropin (hMG) until follicles of 20 mm were identified by transvaginal ultrasound (Standard group).
    Summary · context
    Patients with a poor response in the Standard cycle were treated in the subsequent cycle with N and hMG initially in a similar manner, then N was stopped after 5 days of hMG stimulation (N-stop group).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.